Jennifer A Wargo

Jennifer A Wargo

UNVERIFIED PROFILE

Are you Jennifer A Wargo?   Register this Author

Register author
Jennifer A Wargo

Jennifer A Wargo

Publications by authors named "Jennifer A Wargo"

Are you Jennifer A Wargo?   Register this Author

100Publications

4193Reads

43Profile Views

Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy.

Front Immunol 2018 4;9:946. Epub 2018 May 4.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.00946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945998PMC
July 2019

The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies.

Surg Oncol Clin N Am 2019 Jul;28(3):369-386

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.soc.2019.02.008DOI Listing
July 2019

Neoadjuvant therapy for melanoma: is it ready for prime time?

Lancet Oncol 2019 Jul 3;20(7):892-894. Epub 2019 Jun 3.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 77030; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 77030. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30377-8DOI Listing
July 2019

Immunotherapy resistance: the answers lie ahead - not in front - of us.

J Immunother Cancer 2017 21;5:10. Epub 2017 Feb 21.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit Number 1484, Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0212-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319188PMC
March 2019

A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF /AXL melanoma.

Pigment Cell Melanoma Res 2019 03 19;32(2):280-291. Epub 2018 Oct 19.

Manchester Cancer Research Centre, Faculty of Biology, Medicine & Health, Division of Cancer Sciences, The University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pcmr.12741
Publisher Site
http://dx.doi.org/10.1111/pcmr.12741DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392120PMC
March 2019

The microbiome, cancer, and cancer therapy.

Nat Med 2019 03 6;25(3):377-388. Epub 2019 Mar 6.

Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-019-0377-7DOI Listing
March 2019

Modulating the microbiome to improve therapeutic response in cancer.

Lancet Oncol 2019 Feb;20(2):e77-e91

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30952-5DOI Listing
February 2019

The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy.

Trends Immunol 2018 11;39(11):900-920

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA; These authors contributed equally to this work. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14714906183017
Publisher Site
http://dx.doi.org/10.1016/j.it.2018.09.007DOI Listing
November 2018

The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.

Ann Surg Oncol 2018 Jul 2;25(7):1814-1827. Epub 2018 Mar 2.

Department of Surgical Oncology and Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1245/s10434-018-6379-8
Publisher Site
http://dx.doi.org/10.1245/s10434-018-6379-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105272PMC
July 2018

High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma.

Oncoimmunology 2018 26;7(9):e1475874. Epub 2018 Jul 26.

Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2018.1475874DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140585PMC
July 2018

Immune Checkpoint Blockade across the Cancer Care Continuum.

Immunity 2018 06;48(6):1077-1080

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2018.06.003DOI Listing
June 2018

The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy.

Cancer Cell 2018 04;33(4):570-580

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit Number 1484, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Unit 1954, 1881 East Road, Houston, Texas 77054, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.03.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529202PMC
April 2018

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

Cell 2017 Sep 10;170(6):1120-1133.e17. Epub 2017 Aug 10.

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.07.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591072PMC
September 2017

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.

J Exp Med 2017 06 27;214(6):1691-1710. Epub 2017 Apr 27.

Manchester Cancer Research Centre, Faculty of Biology, Medicine, and Health, School of Medical Sciences, Division of Molecular and Clinical Cancer Studies, The University of Manchester, Manchester M13 9PT, England, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20160855DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460994PMC
June 2017

Hallmarks of response to immune checkpoint blockade.

Br J Cancer 2017 Jun 18;117(1):1-7. Epub 2017 May 18.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.136DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520201PMC
June 2017

Interaction of molecular alterations with immune response in melanoma.

Cancer 2017 06;123(S11):2130-2142

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30681DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105277PMC
June 2017

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.

J Cutan Pathol 2017 Feb 21;44(2):158-176. Epub 2016 Dec 21.

Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.12858DOI Listing
February 2017

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Cell 2017 02;168(4):707-723

Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.01.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391692PMC
February 2017

Targeted Therapies Combined With Immune Checkpoint Therapy.

Cancer J 2016 Mar-Apr;22(2):138-46

From the Departments of *Surgical Oncology and †Genomic Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478395PMC
January 2017

Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?

Clin Cancer Res 2017 Jan 11;23(2):327-329. Epub 2016 Nov 11.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241203PMC
January 2017

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Mol Cancer Ther 2016 10 25;15(10):2442-2454. Epub 2016 Jul 25.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079683PMC
http://dx.doi.org/10.1158/1535-7163.MCT-15-0963DOI Listing
October 2016

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Cell 2016 Oct 22;167(2):397-404.e9. Epub 2016 Sep 22.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088716PMC
http://dx.doi.org/10.1016/j.cell.2016.08.069DOI Listing
October 2016

Uveal melanoma: From diagnosis to treatment and the science in between.

Cancer 2016 08 15;122(15):2299-312. Epub 2016 Mar 15.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29727DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567680PMC
August 2016

Monitoring immune responses in the tumor microenvironment.

Curr Opin Immunol 2016 08 27;41:23-31. Epub 2016 May 27.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Unit 1374, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coi.2016.05.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5257261PMC
August 2016

Update on use of aldesleukin for treatment of high-risk metastatic melanoma.

Immunotargets Ther 2015 7;4:79-89. Epub 2015 Apr 7.

Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/ITT.S61590DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918260PMC
July 2016

Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy.

Curr Oncol Rep 2016 07;18(7):42

Department of Surgical Oncology, Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-016-0531-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330383PMC
July 2016

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.

PLoS One 2015 13;10(10):e0140310. Epub 2015 Oct 13.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States of America; Dermatology and Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140310PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604168PMC
June 2016

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.

Cancer Cell 2016 Mar;29(3):270-284

Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix Research, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796027PMC
March 2016

Novel Treatments in Development for Melanoma.

Cancer Treat Res 2016 ;167:371-416

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-22539-5_16DOI Listing
January 2016

BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.

J Invest Dermatol 2015 Dec 24;135(12):3115-3124. Epub 2015 Aug 24.

The Department of Tumor Biology, The Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; The Department of Cutaneous Oncology, The Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2015.329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648653PMC
December 2015

Working with Human Tissues for Translational Cancer Research.

J Vis Exp 2015 Nov 26(105). Epub 2015 Nov 26.

Department of Surgical Oncology, University of Texas MD Anderson Cancer Center;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/53189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692755PMC
November 2015

Raising the bar: optimizing combinations of targeted therapy and immunotherapy.

Ann Transl Med 2015 Oct;3(18):272

1 Department of Surgical Oncology; 2 Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2305-5839.2015.10.28DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630548PMC
October 2015

Cancer Genomics in Clinical Context.

Trends Cancer 2015 Sep 28;1(1):36-43. Epub 2015 Sep 28.

Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2015.07.010DOI Listing
September 2015

YAP in MAPK pathway targeted therapy resistance.

Cell Cycle 2015 ;14(12):1765-6

a Department of Medicine ; Boston , MA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2015.1032644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612653PMC
August 2015

Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.

Semin Oncol 2015 Aug 3;42(4):601-16. Epub 2015 Jun 3.

Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00937754150010
Publisher Site
http://dx.doi.org/10.1053/j.seminoncol.2015.05.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955940PMC
August 2015

MITF Modulates Therapeutic Resistance through EGFR Signaling.

J Invest Dermatol 2015 Jul 19;135(7):1863-1872. Epub 2015 Mar 19.

Wellman Center for Photomedicine/Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2015.105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466007PMC
July 2015

Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy.

Clin Cancer Res 2015 Jul 29;21(14):3102-4. Epub 2015 May 29.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0363DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506225PMC
July 2015

Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations.

J Cutan Pathol 2015 May 24;42(5):308-17. Epub 2015 Mar 24.

Department of Pathology and Laboratory Medicine, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.12481DOI Listing
May 2015

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

Cancer Discov 2015 Mar 26;5(3):274-87. Epub 2014 Dec 26.

Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts. Department of Dermatology, Harvard Medical School, Boston, Massachusetts. MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0295DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355085PMC
March 2015

Universes collide: combining immunotherapy with targeted therapy for cancer.

Cancer Discov 2014 Dec 13;4(12):1377-86. Epub 2014 Nov 13.

Department of Medical Oncology, Massachusetts General Hospital and Harvard University, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0477DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258160PMC
December 2014

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.

Cancer Biol Med 2014 Dec;11(4):237-46

1 Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA ; 2 Harvard Medical School, Boston, MA 02115, USA ; 3 Department of Melanoma Medical Oncology, 4 Department of Genomic Medicine, 5 Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7497/j.issn.2095-3941.2014.04.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296084PMC
December 2014

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma.

Oncoimmunology 2014 Oct 13;3(9):e954956. Epub 2014 Dec 13.

Division of Surgical Oncology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA ; Genomic Medicine; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/21624011.2014.954956DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292518PMC
October 2014